No Data
No Data
No Data
No Data
No Data
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
BenzingaApr 17 09:13 ET
Express News | Clearmind Medicine Announced An Exclusive Licensing Agreement With Yissum Research Development Company Of The Hebrew University Of Jerusalem For Generation 3.0 Psychedelic Compounds For The Treatment Of Mental Disorders
Moomoo 24/7Apr 17 07:50 ET
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of no
Clearmind MedicineApr 17 00:00 ET
Express News | Clearmind Medicine Announced That It Has Filed A Patent Application With United States Patent And Trademark Office For Psychedelic-based Treatment For Eating Disorders
Moomoo 24/7Apr 10 07:20 ET
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Vancouver, Canada, April 10, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel
Clearmind MedicineApr 10 00:00 ET
Express News | Clearmind Medicine CEO Issues Letter To Shareholders; Says Poised To Achieve Significant Milestones That It Hopes To Substantially Enhance Shareholder Value Through 2024
Moomoo 24/7Apr 9 08:09 ET
No Data
No Data